nodes	percent_of_prediction	percent_of_DWPC	metapath
Ketorolac—Infection—Bleomycin—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Ketorolac—Anaemia—Carmustine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Ketorolac—Back pain—Vincristine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Ketorolac—Vomiting—Teniposide—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Ketorolac—Sepsis—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Ketorolac—Agitation—Carmustine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Ketorolac—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Ketorolac—Asthenia—Fludarabine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Ketorolac—Rash—Teniposide—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Ketorolac—Dermatitis—Teniposide—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Ketorolac—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Ketorolac—Headache—Teniposide—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Ketorolac—Pruritus—Fludarabine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Ketorolac—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Ketorolac—Back pain—Mitoxantrone—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Ketorolac—Leukopenia—Carmustine—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Ketorolac—Anorexia—Bleomycin—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Ketorolac—Anaemia—Vincristine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Ketorolac—Agitation—Vincristine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Ketorolac—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Ketorolac—Photosensitivity—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Ketorolac—Polyuria—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Ketorolac—Hypotension—Bleomycin—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Ketorolac—Diarrhoea—Fludarabine—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Ketorolac—Convulsion—Carmustine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Ketorolac—Hypertension—Carmustine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Ketorolac—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Ketorolac—Nausea—Teniposide—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Ketorolac—Anaemia—Mitoxantrone—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Ketorolac—Vertigo—Vincristine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Ketorolac—Hepatic failure—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Ketorolac—Leukopenia—Vincristine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Ketorolac—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Ketorolac—Chest pain—Carmustine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Ketorolac—Myalgia—Carmustine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Ketorolac—Anxiety—Carmustine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Ketorolac—Paraesthesia—Bleomycin—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Ketorolac—Malaise—Mitoxantrone—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Ketorolac—Dyspnoea—Bleomycin—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Ketorolac—Renal failure acute—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Ketorolac—Leukopenia—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Ketorolac—Convulsion—Vincristine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Ketorolac—Hypertension—Vincristine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Ketorolac—Confusional state—Carmustine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Ketorolac—Oedema—Carmustine—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Ketorolac—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Ketorolac—Decreased appetite—Bleomycin—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Ketorolac—Myalgia—Vincristine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Ketorolac—Visual disturbance—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Ketorolac—Cough—Mitoxantrone—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Ketorolac—Infection—Carmustine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Ketorolac—Vomiting—Fludarabine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Ketorolac—Convulsion—Mitoxantrone—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Ketorolac—Rash—Fludarabine—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Ketorolac—Dermatitis—Fludarabine—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Ketorolac—Hypertension—Mitoxantrone—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Ketorolac—Pain—Bleomycin—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Ketorolac—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Ketorolac—Headache—Fludarabine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Ketorolac—Tachycardia—Carmustine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Ketorolac—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Ketorolac—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Ketorolac—Myalgia—Mitoxantrone—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Ketorolac—Chest pain—Mitoxantrone—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Ketorolac—Anxiety—Mitoxantrone—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Ketorolac—Discomfort—Mitoxantrone—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Ketorolac—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Ketorolac—Oedema—Vincristine—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Ketorolac—Anorexia—Carmustine—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Ketorolac—Infection—Vincristine—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Ketorolac—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Ketorolac—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Ketorolac—Confusional state—Mitoxantrone—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Ketorolac—Nervous system disorder—Vincristine—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Ketorolac—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Ketorolac—Hypotension—Carmustine—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Ketorolac—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.001	0.001	CcSEcCtD
Ketorolac—Oedema—Mitoxantrone—lymphatic system cancer	0.001	0.001	CcSEcCtD
Ketorolac—Nausea—Fludarabine—lymphatic system cancer	0.001	0.001	CcSEcCtD
Ketorolac—Infection—Mitoxantrone—lymphatic system cancer	0.000995	0.000995	CcSEcCtD
Ketorolac—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000994	0.000994	CcSEcCtD
Ketorolac—Shock—Mitoxantrone—lymphatic system cancer	0.000985	0.000985	CcSEcCtD
Ketorolac—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000981	0.000981	CcSEcCtD
Ketorolac—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00098	0.00098	CcSEcCtD
Ketorolac—Urticaria—Bleomycin—lymphatic system cancer	0.00098	0.00098	CcSEcCtD
Ketorolac—Anorexia—Vincristine—lymphatic system cancer	0.00098	0.00098	CcSEcCtD
Ketorolac—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000977	0.000977	CcSEcCtD
Ketorolac—Body temperature increased—Bleomycin—lymphatic system cancer	0.000975	0.000975	CcSEcCtD
Ketorolac—Insomnia—Carmustine—lymphatic system cancer	0.000974	0.000974	CcSEcCtD
Ketorolac—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000973	0.000973	CcSEcCtD
Ketorolac—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000968	0.000968	CcSEcCtD
Ketorolac—Paraesthesia—Carmustine—lymphatic system cancer	0.000967	0.000967	CcSEcCtD
Ketorolac—Hypotension—Vincristine—lymphatic system cancer	0.000961	0.000961	CcSEcCtD
Ketorolac—Dyspnoea—Carmustine—lymphatic system cancer	0.00096	0.00096	CcSEcCtD
Ketorolac—Somnolence—Carmustine—lymphatic system cancer	0.000957	0.000957	CcSEcCtD
Ketorolac—Anorexia—Mitoxantrone—lymphatic system cancer	0.000954	0.000954	CcSEcCtD
Ketorolac—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000937	0.000937	CcSEcCtD
Ketorolac—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000937	0.000937	CcSEcCtD
Ketorolac—Decreased appetite—Carmustine—lymphatic system cancer	0.000936	0.000936	CcSEcCtD
Ketorolac—Hypotension—Mitoxantrone—lymphatic system cancer	0.000936	0.000936	CcSEcCtD
Ketorolac—Insomnia—Vincristine—lymphatic system cancer	0.00093	0.00093	CcSEcCtD
Ketorolac—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00093	0.00093	CcSEcCtD
Ketorolac—Paraesthesia—Vincristine—lymphatic system cancer	0.000923	0.000923	CcSEcCtD
Ketorolac—Constipation—Carmustine—lymphatic system cancer	0.000921	0.000921	CcSEcCtD
Ketorolac—Pain—Carmustine—lymphatic system cancer	0.000921	0.000921	CcSEcCtD
Ketorolac—Breast disorder—Methotrexate—lymphatic system cancer	0.000917	0.000917	CcSEcCtD
Ketorolac—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000914	0.000914	CcSEcCtD
Ketorolac—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000912	0.000912	CcSEcCtD
Ketorolac—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000909	0.000909	CcSEcCtD
Ketorolac—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000899	0.000899	CcSEcCtD
Ketorolac—Decreased appetite—Vincristine—lymphatic system cancer	0.000894	0.000894	CcSEcCtD
Ketorolac—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000893	0.000893	CcSEcCtD
Ketorolac—Somnolence—Mitoxantrone—lymphatic system cancer	0.00089	0.00089	CcSEcCtD
Ketorolac—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000888	0.000888	CcSEcCtD
Ketorolac—Feeling abnormal—Carmustine—lymphatic system cancer	0.000888	0.000888	CcSEcCtD
Ketorolac—Fatigue—Vincristine—lymphatic system cancer	0.000886	0.000886	CcSEcCtD
Ketorolac—Asthenia—Bleomycin—lymphatic system cancer	0.000885	0.000885	CcSEcCtD
Ketorolac—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000881	0.000881	CcSEcCtD
Ketorolac—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000881	0.000881	CcSEcCtD
Ketorolac—Pain—Vincristine—lymphatic system cancer	0.000879	0.000879	CcSEcCtD
Ketorolac—Constipation—Vincristine—lymphatic system cancer	0.000879	0.000879	CcSEcCtD
Ketorolac—Asthma—Methotrexate—lymphatic system cancer	0.000877	0.000877	CcSEcCtD
Ketorolac—Pruritus—Bleomycin—lymphatic system cancer	0.000873	0.000873	CcSEcCtD
Ketorolac—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00087	0.00087	CcSEcCtD
Ketorolac—Eosinophilia—Methotrexate—lymphatic system cancer	0.000869	0.000869	CcSEcCtD
Ketorolac—Fatigue—Mitoxantrone—lymphatic system cancer	0.000863	0.000863	CcSEcCtD
Ketorolac—Pancreatitis—Methotrexate—lymphatic system cancer	0.00086	0.00086	CcSEcCtD
Ketorolac—Constipation—Mitoxantrone—lymphatic system cancer	0.000856	0.000856	CcSEcCtD
Ketorolac—Pain—Mitoxantrone—lymphatic system cancer	0.000856	0.000856	CcSEcCtD
Ketorolac—Abdominal pain—Carmustine—lymphatic system cancer	0.000851	0.000851	CcSEcCtD
Ketorolac—Body temperature increased—Carmustine—lymphatic system cancer	0.000851	0.000851	CcSEcCtD
Ketorolac—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000841	0.000841	CcSEcCtD
Ketorolac—Pancytopenia—Methotrexate—lymphatic system cancer	0.000833	0.000833	CcSEcCtD
Ketorolac—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000825	0.000825	CcSEcCtD
Ketorolac—Dysuria—Methotrexate—lymphatic system cancer	0.00082	0.00082	CcSEcCtD
Ketorolac—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000819	0.000819	CcSEcCtD
Ketorolac—Abdominal pain—Vincristine—lymphatic system cancer	0.000813	0.000813	CcSEcCtD
Ketorolac—Body temperature increased—Vincristine—lymphatic system cancer	0.000813	0.000813	CcSEcCtD
Ketorolac—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000801	0.000801	CcSEcCtD
Ketorolac—Urticaria—Mitoxantrone—lymphatic system cancer	0.000795	0.000795	CcSEcCtD
Ketorolac—Hypersensitivity—Carmustine—lymphatic system cancer	0.000794	0.000794	CcSEcCtD
Ketorolac—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000792	0.000792	CcSEcCtD
Ketorolac—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000792	0.000792	CcSEcCtD
Ketorolac—Pneumonia—Methotrexate—lymphatic system cancer	0.000787	0.000787	CcSEcCtD
Ketorolac—Vomiting—Bleomycin—lymphatic system cancer	0.000785	0.000785	CcSEcCtD
Ketorolac—Drowsiness—Methotrexate—lymphatic system cancer	0.000782	0.000782	CcSEcCtD
Ketorolac—Rash—Bleomycin—lymphatic system cancer	0.000778	0.000778	CcSEcCtD
Ketorolac—Dermatitis—Bleomycin—lymphatic system cancer	0.000777	0.000777	CcSEcCtD
Ketorolac—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000775	0.000775	CcSEcCtD
Ketorolac—Asthenia—Carmustine—lymphatic system cancer	0.000773	0.000773	CcSEcCtD
Ketorolac—Renal failure—Methotrexate—lymphatic system cancer	0.000769	0.000769	CcSEcCtD
Ketorolac—Stomatitis—Methotrexate—lymphatic system cancer	0.000762	0.000762	CcSEcCtD
Ketorolac—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00076	0.00076	CcSEcCtD
Ketorolac—Hypersensitivity—Vincristine—lymphatic system cancer	0.000757	0.000757	CcSEcCtD
Ketorolac—Sweating—Methotrexate—lymphatic system cancer	0.00075	0.00075	CcSEcCtD
Ketorolac—Haematuria—Methotrexate—lymphatic system cancer	0.000746	0.000746	CcSEcCtD
Ketorolac—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00074	0.00074	CcSEcCtD
Ketorolac—Epistaxis—Methotrexate—lymphatic system cancer	0.000738	0.000738	CcSEcCtD
Ketorolac—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000738	0.000738	CcSEcCtD
Ketorolac—Asthenia—Vincristine—lymphatic system cancer	0.000738	0.000738	CcSEcCtD
Ketorolac—Diarrhoea—Carmustine—lymphatic system cancer	0.000737	0.000737	CcSEcCtD
Ketorolac—Nausea—Bleomycin—lymphatic system cancer	0.000733	0.000733	CcSEcCtD
Ketorolac—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00073	0.00073	CcSEcCtD
Ketorolac—Asthenia—Mitoxantrone—lymphatic system cancer	0.000718	0.000718	CcSEcCtD
Ketorolac—Dizziness—Carmustine—lymphatic system cancer	0.000712	0.000712	CcSEcCtD
Ketorolac—Haemoglobin—Methotrexate—lymphatic system cancer	0.000706	0.000706	CcSEcCtD
Ketorolac—Diarrhoea—Vincristine—lymphatic system cancer	0.000703	0.000703	CcSEcCtD
Ketorolac—Hepatitis—Methotrexate—lymphatic system cancer	0.000702	0.000702	CcSEcCtD
Ketorolac—Haemorrhage—Methotrexate—lymphatic system cancer	0.000702	0.000702	CcSEcCtD
Ketorolac—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000693	0.000693	CcSEcCtD
Ketorolac—Urethral disorder—Methotrexate—lymphatic system cancer	0.000688	0.000688	CcSEcCtD
Ketorolac—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000685	0.000685	CcSEcCtD
Ketorolac—Vomiting—Carmustine—lymphatic system cancer	0.000685	0.000685	CcSEcCtD
Ketorolac—Dizziness—Vincristine—lymphatic system cancer	0.00068	0.00068	CcSEcCtD
Ketorolac—Rash—Carmustine—lymphatic system cancer	0.000679	0.000679	CcSEcCtD
Ketorolac—Dermatitis—Carmustine—lymphatic system cancer	0.000678	0.000678	CcSEcCtD
Ketorolac—Visual impairment—Methotrexate—lymphatic system cancer	0.000677	0.000677	CcSEcCtD
Ketorolac—Headache—Carmustine—lymphatic system cancer	0.000675	0.000675	CcSEcCtD
Ketorolac—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000664	0.000664	CcSEcCtD
Ketorolac—Eye disorder—Methotrexate—lymphatic system cancer	0.000656	0.000656	CcSEcCtD
Ketorolac—Tinnitus—Methotrexate—lymphatic system cancer	0.000655	0.000655	CcSEcCtD
Ketorolac—Vomiting—Vincristine—lymphatic system cancer	0.000654	0.000654	CcSEcCtD
Ketorolac—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000652	0.000652	CcSEcCtD
Ketorolac—Rash—Vincristine—lymphatic system cancer	0.000648	0.000648	CcSEcCtD
Ketorolac—Dermatitis—Vincristine—lymphatic system cancer	0.000648	0.000648	CcSEcCtD
Ketorolac—Headache—Vincristine—lymphatic system cancer	0.000644	0.000644	CcSEcCtD
Ketorolac—Nausea—Carmustine—lymphatic system cancer	0.00064	0.00064	CcSEcCtD
Ketorolac—Angiopathy—Methotrexate—lymphatic system cancer	0.000637	0.000637	CcSEcCtD
Ketorolac—Vomiting—Mitoxantrone—lymphatic system cancer	0.000637	0.000637	CcSEcCtD
Ketorolac—Immune system disorder—Methotrexate—lymphatic system cancer	0.000634	0.000634	CcSEcCtD
Ketorolac—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000633	0.000633	CcSEcCtD
Ketorolac—Rash—Mitoxantrone—lymphatic system cancer	0.000631	0.000631	CcSEcCtD
Ketorolac—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000631	0.000631	CcSEcCtD
Ketorolac—Chills—Methotrexate—lymphatic system cancer	0.00063	0.00063	CcSEcCtD
Ketorolac—Headache—Mitoxantrone—lymphatic system cancer	0.000627	0.000627	CcSEcCtD
Ketorolac—Alopecia—Methotrexate—lymphatic system cancer	0.00062	0.00062	CcSEcCtD
Ketorolac—Mental disorder—Methotrexate—lymphatic system cancer	0.000615	0.000615	CcSEcCtD
Ketorolac—Erythema—Methotrexate—lymphatic system cancer	0.000611	0.000611	CcSEcCtD
Ketorolac—Malnutrition—Methotrexate—lymphatic system cancer	0.000611	0.000611	CcSEcCtD
Ketorolac—Nausea—Vincristine—lymphatic system cancer	0.000611	0.000611	CcSEcCtD
Ketorolac—Dysgeusia—Methotrexate—lymphatic system cancer	0.000599	0.000599	CcSEcCtD
Ketorolac—Nausea—Mitoxantrone—lymphatic system cancer	0.000595	0.000595	CcSEcCtD
Ketorolac—Back pain—Methotrexate—lymphatic system cancer	0.000591	0.000591	CcSEcCtD
Ketorolac—Vision blurred—Methotrexate—lymphatic system cancer	0.000576	0.000576	CcSEcCtD
Ketorolac—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000567	0.000567	CcSEcCtD
Ketorolac—Anaemia—Methotrexate—lymphatic system cancer	0.000565	0.000565	CcSEcCtD
Ketorolac—Malaise—Methotrexate—lymphatic system cancer	0.000551	0.000551	CcSEcCtD
Ketorolac—Vertigo—Methotrexate—lymphatic system cancer	0.000549	0.000549	CcSEcCtD
Ketorolac—Leukopenia—Methotrexate—lymphatic system cancer	0.000547	0.000547	CcSEcCtD
Ketorolac—Cough—Methotrexate—lymphatic system cancer	0.000533	0.000533	CcSEcCtD
Ketorolac—Convulsion—Methotrexate—lymphatic system cancer	0.00053	0.00053	CcSEcCtD
Ketorolac—Arthralgia—Methotrexate—lymphatic system cancer	0.00052	0.00052	CcSEcCtD
Ketorolac—Myalgia—Methotrexate—lymphatic system cancer	0.00052	0.00052	CcSEcCtD
Ketorolac—Chest pain—Methotrexate—lymphatic system cancer	0.00052	0.00052	CcSEcCtD
Ketorolac—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000517	0.000517	CcSEcCtD
Ketorolac—Discomfort—Methotrexate—lymphatic system cancer	0.000514	0.000514	CcSEcCtD
Ketorolac—Confusional state—Methotrexate—lymphatic system cancer	0.000503	0.000503	CcSEcCtD
Ketorolac—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000499	0.000499	CcSEcCtD
Ketorolac—Infection—Methotrexate—lymphatic system cancer	0.000496	0.000496	CcSEcCtD
Ketorolac—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000489	0.000489	CcSEcCtD
Ketorolac—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000488	0.000488	CcSEcCtD
Ketorolac—Skin disorder—Methotrexate—lymphatic system cancer	0.000485	0.000485	CcSEcCtD
Ketorolac—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000482	0.000482	CcSEcCtD
Ketorolac—Anorexia—Methotrexate—lymphatic system cancer	0.000476	0.000476	CcSEcCtD
Ketorolac—Hypotension—Methotrexate—lymphatic system cancer	0.000466	0.000466	CcSEcCtD
Ketorolac—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000455	0.000455	CcSEcCtD
Ketorolac—Insomnia—Methotrexate—lymphatic system cancer	0.000451	0.000451	CcSEcCtD
Ketorolac—Paraesthesia—Methotrexate—lymphatic system cancer	0.000448	0.000448	CcSEcCtD
Ketorolac—Dyspnoea—Methotrexate—lymphatic system cancer	0.000445	0.000445	CcSEcCtD
Ketorolac—Somnolence—Methotrexate—lymphatic system cancer	0.000443	0.000443	CcSEcCtD
Ketorolac—Dyspepsia—Methotrexate—lymphatic system cancer	0.000439	0.000439	CcSEcCtD
Ketorolac—Decreased appetite—Methotrexate—lymphatic system cancer	0.000434	0.000434	CcSEcCtD
Ketorolac—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000431	0.000431	CcSEcCtD
Ketorolac—Fatigue—Methotrexate—lymphatic system cancer	0.00043	0.00043	CcSEcCtD
Ketorolac—Pain—Methotrexate—lymphatic system cancer	0.000427	0.000427	CcSEcCtD
Ketorolac—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000411	0.000411	CcSEcCtD
Ketorolac—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000408	0.000408	CcSEcCtD
Ketorolac—Urticaria—Methotrexate—lymphatic system cancer	0.000396	0.000396	CcSEcCtD
Ketorolac—Abdominal pain—Methotrexate—lymphatic system cancer	0.000394	0.000394	CcSEcCtD
Ketorolac—Body temperature increased—Methotrexate—lymphatic system cancer	0.000394	0.000394	CcSEcCtD
Ketorolac—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000368	0.000368	CcSEcCtD
Ketorolac—Asthenia—Methotrexate—lymphatic system cancer	0.000358	0.000358	CcSEcCtD
Ketorolac—Pruritus—Methotrexate—lymphatic system cancer	0.000353	0.000353	CcSEcCtD
Ketorolac—Diarrhoea—Methotrexate—lymphatic system cancer	0.000341	0.000341	CcSEcCtD
Ketorolac—Dizziness—Methotrexate—lymphatic system cancer	0.00033	0.00033	CcSEcCtD
Ketorolac—Vomiting—Methotrexate—lymphatic system cancer	0.000317	0.000317	CcSEcCtD
Ketorolac—Rash—Methotrexate—lymphatic system cancer	0.000315	0.000315	CcSEcCtD
Ketorolac—Dermatitis—Methotrexate—lymphatic system cancer	0.000314	0.000314	CcSEcCtD
Ketorolac—Headache—Methotrexate—lymphatic system cancer	0.000313	0.000313	CcSEcCtD
Ketorolac—Nausea—Methotrexate—lymphatic system cancer	0.000296	0.000296	CcSEcCtD
